Radium-223

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerEfficacy

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 3

212

Paraplatin

AAvyxa

Phase 3

253

Alinamin

Roche

Phase 3

64

Tecentriq

Roche

Phase 3

65

Verzenio

Eli Lilly

Phase 3

46

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

127

GM-CSF

YY-mAbs Therapeutics

Phase 3

88

Radium-223

Bayer

Phase 3

69

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer6 trials

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT05383079·36 enrolled

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·UUniversity of Utah·Phase 1·NCT04109729·39 enrolled

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT03574571·732 enrolled

Show 3 more trials

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Active, not recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT03230734·70 enrolled

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02278055·29 enrolled

Radium-223 in Biochemically Recurrent Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04206319·19 enrolled

mCRPC2 trials

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02463799·36 enrolled

Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

Completed·MMedSIR·Phase 2·NCT03002220·52 enrolled

Metastatic Prostate Cancer2 trials

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed·Pfizer··NCT05701007·1,083 enrolled

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04037358·64 enrolled

Fatigue1 trial

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

Completed·RRadboud University Medical Center··NCT04995614·122 enrolled

Renal Cell Carcinoma1 trial

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Completed·—·Phase 1·NCT02406521·30 enrolled

7 more indications

Observational Study1 trial

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Completed·Bayer··NCT03563014·164 enrolled

Hormone Therapy1 trial

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Completed·Bayer··NCT03896984·346 enrolled

Efficacy1 trial

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Active, not recruiting·UUniversity of California, San Francisco·Phase 2·NCT05924672·2 enrolled

Pembrolizumab1 trial

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Completed·—·Phase 2·NCT03093428·45 enrolled

Urothelial Carcinoma1 trial

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03208712·1 enrolled

Progression-Free Survival1 trial

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

Withdrawn·GGenesisCare USA·Phase 3·NCT05771896

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Recruiting·AstraZeneca·Phase 3·NCT07611110·670 enrolled

Details

Drug Info

Related News